Sumitomo Chemical Company, Limited

Sumitomo Pharmaceuticals Company Limited

Norihiko Tanno

Hisao Tobiki

Takenari Nakagome

Hirotada Yamada

Kozo Shimago

Hiroshi Noguchi

Toshiaki Komatsu

Yasuko Eda

Akio Izawa

Kenji Irie

Kikuo Ishizumi

Ryu Nagata

Ikutaro Saji

Hiromi Sato

Kosaku Okamura

Shiro Terashima

Kenji Koga

Noboru Yoshida

Mayumi Yoshigi

Kousaku Okamura

Toru Kodo

Michihisa Muramatsu

Nobuyuki Ae

Masayuki Muto

Hiroshi Yamaguchi

Naohito Ohashi

Iwao Nakatsuka

Hiroaki Masumori

Masaru Fukui

Yoshihiko Kimura

Yukio Ozaki

Shinzi Ueda

Shinya Morisada

Yasuhisa Sakamaki

Takashi Harimoto

An imide compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which B is a carbonyl group or a sulfonyl group, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each a hydrogen atom or a lower alkyl group, or R.sup.1 and R.sup.2 or R.sup.1 and R.sup.3 may be combined together to make a non-aromatic hydrocarbon ring or R.sup.1 and R.sup.3 may be combined together to make an aromatic ring, said non-aromatic hydrocarbon ring being optionally bridged with a lower alkylene group or an oxygen atom therein and said aromatic ring, said non-aromatic hydrocarbon ring and said lower alkylene group being each optionally substituted with at least one lower alkyl, and n is an integer of 0 or 1;

Imide derivatives and their production and use

A tricyclic quinoxalinedione derivative represented by the formula 1: ##STR1## wherein X represents hydrogen, alkyl, halogen, cyano, trifluoromethyl, or nitro;

Tricyclic quinoxalinedione derivatives

Tricyclic quinoxalinediones

An imide compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which the substituents are defined herein, and n is an integer of 0 to 1;

Imide derivatives, and their production and use

A tricyclic indole-2-carboxylic acid derivative represented by the formula 1: ##STR1## wherein X represents alkyl, halogen or cyano;

Tricyclic indole-2-carboxylic acid derivatives

A novel thiazole derivative represented by the following general formula [1] and a pharmaceutically acceptable salt thereof: ##STR1## wherein A is a single bond, a straight-chained or branched lower alkylene group or a straight-chained or branched lower alkenylene group; B is a single bond or --CO--; R.sup.1 is a carboxy group or --CON(R.sup.7)OR.sup.8 (R.sup.7 and R.sup.8 are independently of each other a hydrogen atom or a lower alkyl group); R.sup.2 is a lower alkyl group; R.sup.3 and R.sup.4 are independently of each other a hydrogen atom, a lower alkyl group or a lower alkoxycarbonyl group; R.sup.5 is a hydrogen atom or a halogen atom; and R.sup.6 is a hydrogen atom, a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a thiol group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a nitro group, an amino group, a substituted amino group, a cyano group, a carboxy group or an acyl group. The compounds of the present invention are useful as therapeutic or preventive drugs for autoimmune diseases and inflammatory diseases.

Thiazole derivatives

A stabilized preparation, particularly, freeze-drying injection, of anthracycline, for example, (7S, 9S)-9-acetyl-9-amino-7-[(2-deoxy-.beta.-D-erythropentopyranosyl)oxy]-7,8,9 ,10-tetrahydro-6,11-dihydroxynaphthacene-5,12-dione or salts thereof which comprises L-cysteine or salts thereof.

Stabilized anthracycline preparation containing L-cysteine

9-Aminonaphthacene derivative having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are both hydrogen atoms or either one of them is a hydrogen atom and the other is hydroxy group or methoxy group; R.sup.3 is acetyl group or 1-hydroxyethyl group; R.sup.4 is a hydrogen atom; R.sup.5 is a hydrogen atom, hydroxy group, lower alkanoyloxy group, amino group, halogen-substituted lower alkanoylamino group or morpholino group; R.sup.6 is a hydrogen atom, hydroxy group, lower alkanoyloxy group or tetrahydropyranyloxy group; R.sup.7 is a hydrogen atom or methyl group; R is a hydrogen atom; and n is zero or one, which is useful as anti-cancer chemical agents with lower toxicity and with little local irritation and is able to orally be applied.

Aminonaphthacene derivatives

A (7S,9S) isomer or its racemic modification of the aminonaphthacene derivative of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom, a hydroxyl group or a lower alkoxy group, R.sup.2 is a hydrogen atom or a hydroxyl group, R.sup.3 and R.sup.4 are each a lower alkoxy group or, when taken together, represent an ethylenedioxy group or an oxo group, A is an ethylene group optionally bearing at least one lower alkyl and Q is a hydroxyl group, a lower alkoxy group or a dimethylamino group, or an acid addition salt thereof, which is useful as an anti-tumor agent.

Aminonaphthacene derivatives and their production

An aminonaphthacene derivative of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom, a hydroxyl group or a lower alkoxy group, R.sup.2 is a hydrogen atom or a hydroxyl group, R.sup.3 is a hydrogen atom or a lower alkanoyl group and R.sup.4 and R.sup.5 are, same or different, each a hydrogen atom, a lower alkyl group, a lower hydroxyalkyl group or a group of the formula: ##STR2## wherein A is an alkylene group which may have one or more lower alkyl substituent(s) and R.sup.6 and R.sup.7 are, same or different, each a hydrogen atom, a lower alkyl group, a lower hydroxyalkyl group or a lower aminoalkyl group, and an acid addition salt thereof, which is useful as anti-tumor agent.

Novel aminonaphthacene derivatives and process for preparation thereof

2-(1'-hydroxy)ethyl-5,8-dimethoxy-3,4-dihydronaphthalene of the formula ##STR1## is produced by reducing 2-acetyl-5,8-dimethoxy-3,4-dihydronaphthalene of the formula, ##STR2## with a reducing agent obtained by reacting one equivalent of lithium aluminum hydride with one equivalent of an optically active N-substituted ephedrine of the formula, ##STR3## (wherein R.sub.1 is a C.sub.1 -C.sub.4 alkyl group or benzyl group, and Ph is phenyl group) and two equivalents of an N-substituted aniline of the formula, ##STR4## (wherein R.sub.2 is a C.sub.1 -C.sub.4 alkyl group or phenyl group, and Ph is phenyl group).

Process for producing dihydronaphthalene derivatives

Novel modified lithium aluminum hydride type reducing agents obtained by reacting one equivalent of lithium aluminum hydride with one equivalent of an optically active N-substituted ephedrine of the formula, ##STR1## (wherein R.sub.1 is a C.sub.1 -C.sub.4 alkyl group or benzyl group, and Ph is phenyl group) and two equivalents of an N-substituted aniline of the formula, ##STR2## (wherein R.sub.2 is C.sub.1 -C.sub.4 alkyl group or phenyl group, and Ph is phenyl group). This reducing agent is usable for reducing the organic compounds having a carbonyl group (ketone group or aldehyde group) in their structure into the corresponding alcohols. It is particularly useful as a reducing agent for asymmetrically reducing the unsymmetrical ketones to selectively produce either an alcohol in which the asymmetric carbon atom bonded to the hydroxy group is in R-configuration or an alcohol in which said asymmetric carbon atom is in S-configuration.

Modified lithium aluminum hydrides

Sodium 6-[D(-)-.alpha.-(4-hydroxy-1,5-naphthyridine-3-carboxamido)phenylacetamido ]penicillanate or its hydroxylated derivative at the p-position of the phenyl group in a crude state can be purified efficiently through its dimethyl sulfoxide adduct.

Dimethyl sulfoxide adducts of penicillins

A cephalosporin derivative of the formula (I), ##STR1## wherein A is a mono- or polycyclic heteroaromatic ring, which contains at least one nitrogen atom as a hetero atom and which may be substituted with one or more substituents; R is a phenyl group substituted with at least one substituent selected from the group consisting of an amino group, a hydroxy group, a ureido group and a hydroxymethyl group; and X is an --OCOCH.sub.3 group or an --S-Het group in which Het is a 5- or 6-membered heterocyclic ring containing one to four hetero atoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which may be substituted with one or more substituents, and the non-toxic pharmaceutically acceptable salts thereof which are useful as an antimicrobial and prepared by the reaction of a compound of the formula (II),

N-acylamino-.alpha.-arylacetamido cephalosporins

N-acylamino-alpha-arylacetamido cephalosporins and antibacterial

Growing community of inventors

Ibaraki, Japan

Norihiko Tanno